



OPEN ACCESS

EDITED AND REVIEWED BY
Donghong Zhang,
Emory University, United States

*CORRESPONDENCE

Ling Lin
✉ llinc@163.net
Yong-Song Chen
✉ yongsongchen@126.com

†These authors have contributed
equally to this work

SPECIALTY SECTION

This article was submitted to
Breast Cancer,
a section of the journal
Frontiers in Oncology

RECEIVED 07 December 2022

ACCEPTED 12 December 2022

PUBLISHED 10 January 2023

CITATION

Li Z-X, Chen J-X, Zheng Z-J, Cai W-J,
Yang X-B, Huang Y-Y, Gong Y, Xu F,
Chen Y-S and Lin L (2023)
Corrigendum: TGF- β 1 promotes
human breast cancer angiogenesis
and malignant behavior by regulating
endothelial-mesenchymal transition.
Front. Oncol. 12:1118572.
doi: 10.3389/fonc.2022.1118572

COPYRIGHT

© 2023 Li, Chen, Zheng, Cai, Yang,
Huang, Gong, Xu, Chen and Lin. This is
an open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use,
distribution or reproduction is
permitted which does not comply
with these terms.

Corrigendum: TGF- β 1 promotes human breast cancer angiogenesis and malignant behavior by regulating endothelial- mesenchymal transition

Zi-Xiong Li^{1,2†}, Jie-Xin Chen^{1†}, Ze-Jun Zheng^{1†},
Wang-Jing Cai^{1†}, Xiong-Bin Yang¹, Yuan-Yuan Huang¹,
Yao Gong³, Feng Xu⁴, Yong-Song Chen^{5*} and Ling Lin^{1,3*}

¹Department of Rheumatology and Immunology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China, ²Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China, ³Department of Rheumatology, Shantou University Medical College, Shantou, China, ⁴Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Shantou University Medical College, Shantou, China, ⁵Department of Endocrinology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China

KEYWORDS

TGF- β 1, EndMT, angiogenesis, breast cancer, BCSLC, dorsal skinfold window chamber

A corrigendum on

TGF- β 1 promotes human breast cancer angiogenesis and malignant behavior by regulating endothelial-mesenchymal transition.

by Li Z-X, Chen J-X, Zheng Z-J, Cai W-J, Yang X-B, Huang Y-Y, Gong Y, Xu F, Chen Y-S and Lin L (2022) *Front. Oncol.* 12:1051148. doi: 10.3389/fonc.2022.1051148

Error in Figure/Table

In the published article, there was an error in [Figure 1](#) High expression of MVD predicted unfavorable prognosis of IDC patients. as published. In [Figure 1B](#), the title of X axis was “Specificity”, it should be corrected to “1-Specificity”. The corrected [Figure 1](#) High expression of MVD predicted unfavorable prognosis of IDC patients. and its caption appear below.

In the published article, there was an error in [Figure 2](#) MVD level is positively correlated with EndMT markers in breast cancer. as published. In [Figure 2A, B](#), the red “#” and green “*” were missing. The corrected [Figure 2](#) MVD level is positively correlated with EndMT markers in breast cancer. and its caption appear below.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 1 High expression of MVD predicted unfavorable prognosis of IDC patients. **(A)** Representative images of immunohistochemical (IHC) staining of vWF and CD34 in samples from breast invasive ductal carcinoma (IDC) patients. **(B)** ROC curve of the CD34 and vWF by the DFS of IDC patients. **(C, D)** Kaplan-Meier analysis of DFS and OS of IDC patients from our cohort by vWF and CD34.




FIGURE 2 MVD level is positively correlated with EndMT markers in breast cancer. **(A, B)** Representative images of double-IHC staining of vWF, CD34 (brown, with red "#") and either α -SMA, FSP-1 or Vimentin (red, with green "**") in samples from IDC patients. **(C–G)** Kaplan-Meier analysis of DFS and OS of IDC patients from our cohort by α -SMA, FSP-1, Vimentin, VE-Cadherin and Fibronectin.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.